Hepatic inflammation reduction

Hepatic inflammation reduction is a physiological process and a primary therapeutic objective in the management of chronic liver diseases, rather than a specific molecular target. It involves the attenuation of inflammatory signaling pathways and the reduction of immune cell recruitment, such as macrophages and neutrophils, into the liver parenchyma (Source: PubMed, PMID: 31535168). This process is critical for halting the progression of metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, and autoimmune liver diseases, which otherwise lead to fibrosis, cirrhosis, and hepatocellular carcinoma (Source: StatPearls, Hepatitis). Pharmacological agents achieve this reduction by targeting specific molecular entities such as the farnesoid X receptor (FXR), thyroid hormone receptor beta (THR-beta), or various peroxisome proliferator-activated receptors (PPARs) (Source: PubChem). Monitoring this process typically involves measuring serum transaminases like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as histological assessment of liver biopsies (Source: NIH, National Institute of Diabetes and Digestive and Kidney Diseases).

Other names

Liver inflammation reductionResolution of hepatic inflammationHepatic anti-inflammatory responseReduction of liver inflammation

Hepatic inflammation reduction is a physiological outcome achieved through various mechanisms depending on the therapeutic agent, including the activation of nuclear receptors (e.g., FXR, PPARs) to modulate gene expression, the inhibition of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), or the modulation of metabolic pathways to reduce lipotoxicity and oxidative stress (Source: PubChem).